A new first-line chemotherapy regimen of prednisone, vinblastine, doxorubicin, and bendamustine (PVAB) yields a high complete metabolic response (CMR) rate with acceptable toxicity in older patients with classical Hodgkin lymphoma (cHL), according to research published in Blood.
This article describes research done by the Childhood Cancer Survivor Study of St. Jude Children’s Research Hospital and CARDIA, which stands for “Coronary Artery Risk Development in Young Adults.” These two organizations combined their data bases to create an in-depth study of the specific risks for childhood cancer survivors. The results are concerning, and they underline the need for early and frequent observation post treatment.
This article in HemOnc Today describes a recent study that evaluated the use of specific biomarkers, namely global longitudinal strain (GLS) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) to identify childhood cancer survivors who may be at risk for cardiomyopathy. The study was done through the St. Jude Lifetime Cohort study.
This research paper takes a look at the risk of breast cancer from doxorubicin exposure in female survivors of Hodgkin lymphoma who are between the ages of 15-50 years of age and five years post treatment. The period of treatment was between 1975 and 2008. The study was first presented in 2021 at the ASCO Annual Meeting.
Of note is that the authors found an increased risk of breast cancer in this cohort independent of whether or not radiation was also a part of the treatment protocol.
During this special patient webinar, you will learn critical insights about new advances in minimally-invasive, robotic heart valve surgery. The featured speakers are Dr. Pavan Atluri, Director of Minimally Invasive and Robotic Cardiac Surgery, and Dr. Michael Ibrahim, Director of Reconstructive Valve Surgery, at Penn Medicine.
This is a “must read” paper for survivors and medical providers. It is exactly what is needed in the world of cancer survivorship–a comprehensive template for insuring that survivors get the care that they need. Download it, pass it on, place it in the hands of your doctors and caretakers.
This article describes the results of a study from the University of California San Francisco. It highlights one of the topics Dr. Micheal Stubblefield mentioned in his presentation at our conference. It comes from a paper that was published in the British Medical Journal Supportive and Palliative Care, July 2022. First author Steven W. Cheung, MD notes the marked incidence of hearing loss and tinnitus in survivors, owing to chemotherapy drugs that contained platinum as well as those that contained taxanes.